Time to address the neglected burden of group A
            <i>Streptococcus</i>

Cannon, J. R.; Bennett, Julie; Baker, Michael G; Carapetis, Jonathan R.

doi:10.5694/mja2.51149

Medical Journal of Australia

2021

DOI: 10.5694/mja2.51149

|View full text |Cite

Time to address the neglected burden of group A Streptococcus

J. R. Cannon

Julie Bennett

Michael G Baker

et al.

Abstract: Estimated number of new cases (left) and deaths (right) due to meningitis and rheumatic heart disease globally** Data obtained from the Global Burden of Disease study 2019. 4 ◆

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2022

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

(1 citation statement)

References 5 publications

(6 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…treptococcus pyogenes is a human-restricted pathogen with a profound and persistent global burden of disease 1 . It is a ubiquitous human pathogen and is responsible for more than 500,000 deaths each year 2,3 . Acute pharyngitis is the most common of all clinical syndromes due to S. pyogenes 4 .…”

mentioning

confidence: 99%

Immune signature of acute pharyngitis in a Streptococcus pyogenes human challenge trial

et al. 2022

View full text Add to dashboard Cite

Streptococcus pyogenes causes at least 750 million infections and more than 500,000 deaths each year. No vaccine is currently available for S. pyogenes and the use of human challenge models offer unique and exciting opportunities to interrogate the immune response to infectious diseases. Here, we use high-dimensional flow cytometric analysis and multiplex cytokine and chemokine assays to study serial blood and saliva samples collected during the early immune response in human participants following challenge with S. pyogenes. We find an immune signature of experimental human pharyngitis characterised by: 1) elevation of serum IL-1Ra, IL-6, IFN-γ, IP-10 and IL-18; 2) increases in peripheral blood innate dendritic cell and monocyte populations; 3) reduced circulation of B cells and CD4+ T cell subsets (Th1, Th17, Treg, TFH) during the acute phase; and 4) activation of unconventional T cell subsets, γδTCR + Vδ2+ T cells and MAIT cells. These findings demonstrate that S. pyogenes infection generates a robust early immune response, which may be important for host protection. Together, these data will help advance research to establish correlates of immune protection and focus the evaluation of vaccines.

show abstract

mentioning

confidence: 99%

Immune signature of acute pharyngitis in a Streptococcus pyogenes human challenge trial

et al. 2022

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Time to address the neglected burden of group A Streptococcus

Abstract: Estimated number of new cases (left) and deaths (right) due to meningitis and rheumatic heart disease globally** Data obtained from the Global Burden of Disease study 2019. 4 ◆

Cited by 1 publication

References 5 publications

Immune signature of acute pharyngitis in a Streptococcus pyogenes human challenge trial

Immune signature of acute pharyngitis in a Streptococcus pyogenes human challenge trial

Contact Info

Product

Resources

About